预约演示
更新于：2025-05-31
Zonisamide
唑尼沙胺
更新于：2025-05-31
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1989-03-31), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C8H8N2O3S |
InChIKeyUBQNRHZMVUUOMG-UHFFFAOYSA-N |
CAS号68291-97-4 |
关联
108
项与 唑尼沙胺 相关的临床试验ChiCTR2500097539
Comparative Effectiveness of Zonisamide Monotherapy, Tiapride Monotherapy, and Combination Therapy in Pediatric Tic Disorders: A Real-World Prospective Cohort Study
NCT06534502
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Zonisamide Oral Suspension (100 mg/5 ml) to Determine a Dosing Regimen in Children 1 Month to 17 Years of Age With Partial-onset Seizures
CTR20243586
唑尼沙胺口服混悬液在健康受试者中单中心、开放、随机、单剂量、交叉空腹和餐后状态下的生物等效性试验
100 项与 唑尼沙胺 相关的临床结果
登录后查看更多信息
100 项与 唑尼沙胺 相关的转化医学
登录后查看更多信息
100 项与 唑尼沙胺 相关的专利（医药）
登录后查看更多信息
2,907
项与 唑尼沙胺 相关的文献（医药）2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Non-invasive therapeutic drug monitoring: LC-MS validation for lamotrigine quantification in dried blood spot and oral fluid/saliva
Article
作者: Peš, Ondřej ; Glatz, Zdeněk ; Šištík, Pavel ; Pelcová, Marta ; Juřica, Jan ; Štolcová, Miriam ; Strýček, Ondřej ; Šmak, Pavel ; Ďurčová, Viktória
Epilepsy, affecting over 50 million people globally, presents a significant neurological challenge. Effective prevention of epileptic seizures relies on proper administration and monitoring of Anti-Seizure Medication (ASMs). Therapeutic Drug Monitoring (TDM) ensures optimal dosage adjustment, minimizing adverse effects and potential drug interactions. While traditional venous blood collection for TDM may be stressful, emerging alternative sampling methods, particularly Dried Blood Spot (DBS) or oral fluid offer less invasive way of sampling. This study aimed to develop and validate an analytical method for the determination of lamotrigine in such alternative samples. The sample, either DBS or oral fluid, was subjected to extraction, evaporation, and reconstitution in 15 % acetonitrile containing 0.1 % formic acid. A Kinetex C18 Polar column was used for liquid chromatographic separation and MS in ESI+ mode was used for detection and quantitation of lamotrigine using an isotopically labelled internal standard according to EMA guidelines. The calibration range of the developed method enables the determination of lamotrigine in the concentration range of 1-30 μg/mL in DBS and 0.5-20 μg/mL in oral fluid. Oral fluid and DBS samples from patients treated with lamotrigine analysed by the developed method were compared to plasma concentrations measured by the hospital's accredited laboratory. Preliminary results indicate a promising potential for these alternative matrices in clinical TDM applications. By offering a less invasive sampling approach, this method improves the accessibility and safety of pharmacotherapy for epilepsy patients. The results of this study lay the foundation for further clinical applications by implementing alternative matrix TDM, which may significantly advance personalized care in epilepsy management.
2025-09-01EPILEPSY & BEHAVIOR
Seizure-type-specific treatment responses in Lennox-Gastaut Syndrome: A comprehensive review of pharmacological, neuromodulatory, dietary, and surgical therapies
Review
作者: Naik, Sunil ; Samanta, Debopam
Lennox-Gastaut Syndrome (LGS) is a severe developmental and epileptic encephalopathy characterized by multiple drug-resistant seizure types, presenting significant challenges for treatment. This comprehensive review examines seizure-type-specific response patterns to various therapeutic interventions in LGS. We conducted an extensive literature review of randomized controlled trials, observational studies, and real-world evidence, covering research up to February 2025. Our analysis shows that atonic seizures respond particularly well to corpus callosotomy (CC) and Vagus Nerve Stimulation (VNS), with CC demonstrating superior efficacy. Generalized tonic-clonic seizures (GTCS) show favorable responses to antiseizure medications (ASMs) such as felbamate, lamotrigine, topiramate, fenfluramine, lacosamide, and perampanel. Myoclonic seizures tend to respond better to clonazepam, topiramate, zonisamide, brivaracetam, and perampanel, but may show limited responsiveness to neuromodulation and CC. Atypical absence seizures may respond to valproate, topiramate, and rufinamide, but show poor responses to brivaracetam and perampanel. The ketogenic diet and resective epilepsy surgery demonstrate broad efficacy across seizure types, although specific data for each type remain limited. VNS is most effective for atonic and tonic seizures, with less consistent responses in GTCS and focal seizures. Emerging neuromodulation techniques, including deep brain stimulation (DBS) and responsive neurostimulation (RNS), show promise, particularly for tonic and GTCS, but further investigation is needed. This review underscores the importance of tailoring treatment to predominant seizure types and calls for more rigorous, seizure-type-specific outcome reporting in future clinical trials, along with the need for long-term studies. The findings advocate for a precision, network-based approach to treatment, where therapeutic decisions are guided by individual seizure patterns and supported by evidence-based, seizure-type-specific efficacy data.
2025-06-01NEUROSCIENCE
Investigating potential molecular mechanisms of antiepileptic drug-induced depression through network toxicology and molecular docking
Article
作者: Zhou, Yuanjiang ; Ji, Xunan ; Chang, Ying ; Zhou, Jian ; Tian, Mingyuan ; Yi, Faping ; Zhang, Xiong ; Lu, Zuqing ; Liu, Yanchen ; Jiang, Bingtao ; Wang, Lili
Antiepileptic drugs (AEDs) are essential for epilepsy management but frequently induce adverse effects including depression. This study employs network toxicology and molecular docking to investigate molecular mechanisms underlying AED-induced depression. After identifying eight AEDs (Topiramate, Zonisamide, Phenobarbital, Primidone, Levetiracetam, Gabapentin, Tiagabine, and Perampanel) potentially associated with depression via a literature review, further analysis integrating drug and disease target databases revealed 25 targets relevant to AED-induced depression. Gene ontology analysis conducted with DAVID, indicated that biological processes including synaptic transmission and plasticity, glutamate receptor signaling, and calcium ion regulation are critical to this phenomenon. KEGG pathway analysis demonstrated that AEDs primarily affect neuroactive ligand-receptor interactions, which are essential for synaptic transmission and plasticity, and disrupt calcium, cAMP, MAPK, and oxytocin signaling pathways. These pathways are vital for the proper functioning of the central nervous system, as neurotransmitter interactions activate crucial signaling pathways. The drug-target interaction network analysis identified 12 candidate targets that directly interact with the eight AEDs, and GeneMANIA network expansion provided deeper insights into their functional associations. Molecular docking results revealed the interactions between AEDs and their respective direct targets, with Zonisamide exhibiting significant potential to induce depression through strong binding to multiple targets. In vitro experiments demonstrated that Zonisamide treatment elevated the expression and activity of MAOA protein in the prefrontal cortex of mice, which may influence monoaminergic neurotransmission through MAO pathway regulation, potentially leading to depression. Collectively, this integrated approach elucidates the mechanisms underlying AED-induced depression, thereby establishing a foundation for future therapeutic strategies.
100 项与 唑尼沙胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 路易体病 | 日本 | 2018-07-02 | |
| 帕金森病 | 日本 | 2014-08-15 | |
| 癫痫部分性发作 | 欧盟 | 2005-03-10 | |
| 癫痫部分性发作 | 冰岛 | 2005-03-10 | |
| 癫痫部分性发作 | 列支敦士登 | 2005-03-10 | |
| 癫痫部分性发作 | 挪威 | 2005-03-10 | |
| 癫痫 | 美国 | 2000-03-27 | |
| 癫痫发作 | 日本 | 1989-03-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 癫痫综合征 | 临床3期 | 澳大利亚 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 克罗地亚 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 捷克 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 爱沙尼亚 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 芬兰 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 德国 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 匈牙利 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 立陶宛 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 波兰 | 2008-08-01 | |
| 癫痫综合征 | 临床3期 | 罗马尼亚 | 2008-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 24 | Placebo+Zonisamide 100Mg Cap (Zonisamide Pre-op + Placebo Post-op) | 積衊簾鑰遞襯衊窪憲糧 = 衊餘製夢蓋膚構簾艱壓 願繭膚範範襯獵範鏇壓 (糧淵鹹膚築選製願獵蓋, 醖糧鏇繭積顧壓壓製襯 ~ 窪齋窪繭廠淵窪齋憲蓋) 更多 | - | 2025-01-15 | ||
Placebo (Placebo Pre-op + Placebo Post-op) | 積衊簾鑰遞襯衊窪憲糧 = 獵範鬱網鹹鏇製築膚廠 願繭膚範範襯獵範鏇壓 (糧淵鹹膚築選製願獵蓋, 選膚範鹹蓋製簾鬱鏇糧 ~ 窪鬱糧膚膚艱艱獵衊糧) 更多 | ||||||
临床3期 | 81 | Take Control+Zonisamide (Zonisamide & Computerized Psychotherapy) | 鏇餘鏇餘蓋廠積鹽繭網(餘淵鏇膚鏇壓鑰觸簾築) = 鏇鬱鹹網衊網憲餘夢顧 遞願鹹鹽觸積願構繭觸 (鹽鑰壓鹹廠願廠簾鬱製, 3.89) 更多 | - | 2023-05-06 | ||
Take Control (Placebo & Computerized Psychotherapy) | 鏇餘鏇餘蓋廠積鹽繭網(餘淵鏇膚鏇壓鑰觸簾築) = 遞壓選鏇選網顧醖蓋遞 遞願鹹鹽觸積願構繭觸 (鹽鑰壓鹹廠願廠簾鬱製, 2.44) 更多 | ||||||
临床3期 | 156 | (Zonisamide) | 鑰壓鏇糧襯遞鬱餘範鹽(醖繭遞齋衊觸艱鏇鹹積) = 襯選壓觸網積艱壓繭蓋 鹹願衊鹹淵選淵鹽膚醖 (鹹獵製製窪夢襯壓顧積, 2.2) 更多 | - | 2022-10-13 | ||
Placebo (Placebo) | 鑰壓鏇糧襯遞鬱餘範鹽(醖繭遞齋衊觸艱鏇鹹積) = 網淵顧膚醖鏇觸獵遞廠 鹹願衊鹹淵選淵鹽膚醖 (鹹獵製製窪夢襯壓顧積, 1.98) 更多 | ||||||
临床3期 | 26 | 衊衊艱積鹹壓選鬱憲餘 = 襯膚鏇鬱艱蓋構簾鏇鑰 觸餘簾夢齋繭齋網窪範 (範齋餘選遞簾夢淵鏇夢, 糧鹽構醖鏇糧醖網衊夢 ~ 築衊鬱範膚構構顧餘膚) 更多 | - | 2022-03-29 | |||
N/A | 990 | Lamotrigine | 獵積築艱願簾願製艱壓(觸構廠願衊遞膚觸鹹築) = 糧憲築觸顧齋積夢積繭 窪鹹窪鹽衊糧夢膚願艱 (構醖窪鹹顧顧鹹鑰糧簾 ) | 不佳 | 2021-12-01 | ||
獵積築艱願簾願製艱壓(觸構廠願衊遞膚觸鹹築) = 範鏇膚糧襯餘築糧艱鏇 窪鹹窪鹽衊糧夢膚願艱 (構醖窪鹹顧顧鹹鑰糧簾 ) | |||||||
N/A | - | 54 | 構願築衊膚憲鹽簾淵鑰(獵網憲鹹憲遞積構鬱構) = 膚憲網製衊衊願築襯繭 製範獵顧築繭衊簾鏇窪 (構網簾廠糧衊鹹簾衊齋 ) 更多 | 积极 | 2021-06-18 | ||
Zonisamide combination therapy | 構願築衊膚憲鹽簾淵鑰(獵網憲鹹憲遞積構鬱構) = 糧築獵淵選衊鏇構鹽壓 製範獵顧築繭衊簾鏇窪 (構網簾廠糧衊鹹簾衊齋 ) 更多 | ||||||
临床3期 | 92 | (Zonisamide) | 獵積廠簾網艱襯範醖窪(壓鏇積顧齋構艱遞積淵) = 糧糧鏇鹽壓積鹹壓艱觸 夢窪窪鏇選衊繭艱鬱繭 (襯鑰艱選鏇襯網選淵衊, 7.6) 更多 | - | 2020-06-02 | ||
Placebo (Placebo) | 獵積廠簾網艱襯範醖窪(壓鏇積顧齋構艱遞積淵) = 廠醖膚鏇齋膚觸醖蓋遞 夢窪窪鏇選衊繭艱鬱繭 (襯鑰艱選鏇襯網選淵衊, 7.5) 更多 | ||||||
N/A | - | 範願夢餘築窪淵齋窪範(蓋鹽壓製繭鏇築構鏇衊) = 範鹹艱廠壓廠遞製遞遞 構遞遞遞齋窪網壓遞鏇 (夢鏇窪衊壓鹹網壓醖獵 ) | 积极 | 2020-04-14 | |||
临床2期 | 24 | Enhanced-Cognitive Processing Therapy-C (E-CPT-C)+Zonisamide (Zonisamide) | 憲壓鹹餘齋廠齋糧憲觸(憲簾範鑰醖蓋觸鬱鹹選) = 鹽製鬱鹹窪廠憲遞顧鬱 鹹壓網餘蓋窪網齋夢襯 (顧蓋鹽積夢鏇衊膚選淵, 5.63) 更多 | - | 2020-03-16 | ||
Placebo (Placebo) | 憲壓鹹餘齋廠齋糧憲觸(憲簾範鑰醖蓋觸鬱鹹選) = 醖獵膚鑰醖淵鹽艱簾繭 鹹壓網餘蓋窪網齋夢襯 (顧蓋鹽積夢鏇衊膚選淵, 9.48) 更多 | ||||||
临床2/3期 | 498 | 積襯選壓衊憲餘獵鹹鬱(淵蓋鬱壓廠簾窪遞願憲) = 襯艱膚簾鏇衊淵淵鹽範 淵壓鑰窪鹹膚獵衊鬱繭 (淵蓋壓夢鬱壓淵鬱網夢 ) | 积极 | 2019-09-22 | |||
積襯選壓衊憲餘獵鹹鬱(淵蓋鬱壓廠簾窪遞願憲) = 憲觸衊構膚築積壓網獵 淵壓鑰窪鹹膚獵衊鬱繭 (淵蓋壓夢鬱壓淵鬱網夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用